论文部分内容阅读
目的观察凯时(lipoPGE1)治疗糖尿病肾病(DN)的临床疗效,并探讨其肾脏保护作用的机制。方法选择本院住院的2型糖尿病肾病120例,随机分为治疗组60例及对照组60例。两组均在糖尿病常规治疗(包括严格控制饮食、适量运动,口服降糖药或胰岛素治疗)的同时进行试验。治疗组加用凯时注射液治疗,疗程28d。观察两组治疗前后及组间24h尿白蛋白总量、血尿素氮和肌酐等相关指标的变化,并观察有无副作用。结果治疗组尿微量白蛋白及24h尿白蛋白总量、血尿素氮、肌酐降低,肾功能明显改善,与治疗前及对照组比较有显著性差异(P<0.05)。结论凯时明显改善糖尿病肾病的尿微量白蛋白、24h尿白蛋白总量及肾功能等指标,是一种治疗糖尿病肾病安全、有效的药物。
Objective To observe the clinical efficacy of lipoPGE1 in the treatment of diabetic nephropathy (DN) and to explore its mechanism of renal protective effect. Methods 120 cases of type 2 diabetic nephropathy hospitalized in our hospital were randomly divided into treatment group (60 cases) and control group (60 cases). Both groups were tested at the same time as conventional diabetes treatment (including strict diet control, moderate exercise, oral hypoglycemic agents or insulin therapy). Treatment group plus Kay hours injection treatment, treatment 28d. The changes of 24 hours urinary albumin, blood urea nitrogen and creatinine were observed before and after treatment and between the two groups, and the side effects were observed. Results The total urinary albumin, urinary albumin, blood urea nitrogen, creatinine and renal function in the treatment group were significantly improved (P <0.05) compared with those before treatment and the control group. Conclusions Kaixin significantly improves urinary microalbuminuria, 24-hour urinary albumin and renal function in diabetic nephropathy, which is a safe and effective drug for the treatment of diabetic nephropathy.